Relay Therapeutics, Inc. (RLAY)
18.69
+0.18
(+0.97%)
USD |
NASDAQ |
Sep 03, 10:42
Relay Therapeutics Research and Development Expense (TTM) : 270.72M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 270.72M |
| March 31, 2026 | 258.14M |
| December 31, 2025 | 261.38M |
| September 30, 2025 | 274.04M |
| June 30, 2025 | 282.40M |
| March 31, 2025 | 310.50M |
| December 31, 2024 | 319.09M |
| September 30, 2024 | 328.51M |
| June 30, 2024 | 333.38M |
| March 31, 2024 | 329.59M |
| December 31, 2023 | 330.02M |
| September 30, 2023 | 319.80M |
| June 30, 2023 | 305.20M |
| March 31, 2023 | 277.52M |
| Date | Value |
|---|---|
| December 31, 2022 | 246.36M |
| September 30, 2022 | 230.16M |
| June 30, 2022 | 207.43M |
| March 31, 2022 | 191.30M |
| December 31, 2021 | 169.53M |
| September 30, 2021 | 149.87M |
| June 30, 2021 | 129.32M |
| March 31, 2021 | 105.89M |
| December 31, 2020 | 96.98M |
| September 30, 2020 | 87.26M |
| June 30, 2020 | 81.26M |
| March 31, 2020 | 76.12M |
| December 31, 2019 | 67.89M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie, Inc. | 9.714B |
| TG Therapeutics, Inc. | 225.80M |
| Karyopharm Therapeutics, Inc. | 120.81M |
| Krystal Biotech, Inc. | 53.39M |
| Akebia Therapeutics, Inc. | 68.91M |